Penn Capital Management Company LLC Lowers Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Penn Capital Management Company LLC lessened its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 10.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 278,427 shares of the company’s stock after selling 30,817 shares during the period. Penn Capital Management Company LLC owned 0.58% of Mirum Pharmaceuticals worth $11,513,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of MIRM. Summit Investment Advisors Inc. grew its position in shares of Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after purchasing an additional 312 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares in the last quarter. Legato Capital Management LLC raised its position in shares of Mirum Pharmaceuticals by 7.9% during the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after buying an additional 977 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after buying an additional 1,003 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Mirum Pharmaceuticals by 2.4% during the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after acquiring an additional 1,236 shares during the last quarter.

Mirum Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:MIRM opened at $39.62 on Thursday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business has a 50 day simple moving average of $44.55 and a two-hundred day simple moving average of $43.94. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The firm has a market capitalization of $1.96 billion, a PE ratio of -19.61 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares in the company, valued at $214,698.35. This trade represents a 92.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 6,837 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $327,629.04. Following the completion of the sale, the chief executive officer now owns 125,022 shares of the company’s stock, valued at $5,991,054.24. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,473 shares of company stock valued at $5,249,134 in the last three months. Company insiders own 22.87% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on MIRM shares. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.